Background: The cytokine transforming growth factor-β(TGF-β) has important regulatory roles in the immune system. To investigate the role of intact TGF-β signaling during the contact hypersensitivity (CHS) response to a respiratory allergen, we exposed Smad3–/– mice to topical trimellitic anhydride (TMA). Methods: CHS was induced by topical application of TMA. The swelling of the TMA-exposed ears was analyzed, and lymph node, ear tissue and skin biopsies were collected for RNA isolation, histology and histochemical analyses. Lymph node cell proliferation was measured and blood samples were collected for analysis of TMA-specific immunoglobulin. Results: Topical TMA exposure resulted in increased mRNA expression of proinflammatory and suppressive cytokines (IL-1β, TNF-α, IL-6, IFN-γ, IL-4, IL-10, IL-17, IL-23, TGF-β), chemokines (CXCL9, CXCL10, CCL24) and chemokine receptors (CCR7, CCR8, CXCR2), increased numbers of CD3+ T cells in ear tissue, and lymphadenopathy in the Smad3–/– mice. The IL-10 result was confirmed at the protein level by immunohistochemistry. However, the ear-swelling response and infiltration of eosinophils, F4/80+ cells, CD11c+ cells and mast cells were similar in the Smad3–/– mice compared to their wild-type (WT) siblings. While TMA-specific IgE was induced equally in the WT and Smad3–/– mice, the concentration of TMA-specific IgG2a was significantly lower in the Smad3–/– mice. Conclusions: The Smad3 molecule contributes significantly to the regulation of the cytokine and chemokine network during the CHS response to TMA. The lack of Smad3 resulted in a potent Th2 shift, confirmed by strongly impaired IgG2a levels.

Keywords:
Smad3, Trimellitic anhydride, allergy, Skin inflammation
1.
Dearman RJ, Basketter DA, Kimber I: Differential cytokine production following chronic exposure of mice to chemical respiratory and contact allergens. Immunology 1995;86:545–550.
2.
Dearman RJ, Kimber I: Cytokine fingerprinting: characterization of chemical allergens. Methods 1999;19:56–63.
3.
Letterio JJ, Roberts AB: Regulation of immune responses by TGF-β. Annu Rev Immunol 1998;16:137–161.
4.
Veldhoen M, Stockinger B: TGFβ1, a ‘Jack of all trades’: the link with pro-inflammatory IL-17-producing t cells. Trends Immunol 2006;27:358–361.
5.
Veldhoen M, Hocking RJ, Atkins CJ, Locksley RM, Stockinger B: TGFβ in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing t cells. Immunity 2006;24:179–189.
6.
He D, Wu L, Kim HK, Li H, Elmets CA, Xu H: CD8+ IL-17-producing T cells are important in effector functions for the elicitation of contact hypersensitivity responses. J Immunol 2006;177:6852–6858.
7.
Gorelik L, Flavell RA: Transforming growth factor-β in T-cell biology. Nat Rev Immunol 2002;2:46–53.
8.
Bogdan C, Nathan C: Modulation of macrophage function by transforming growth factor β, interleukin-4, and interleukin-10. Ann N Y Acad Sci 1993;685:713–739.
9.
Geissmann F, Revy P, Regnault A, Lepelletier Y, Dy M, Brousse N, Amigorena S, Hermine O, Durandy A: TGF-β 1 prevents the noncognate maturation of human dendritic Langerhans cells. J Immunol 1999;162:4567–4575.
10.
Piccirillo CA, Letterio JJ, Thornton AM, McHugh RS, Mamura M, Mizuhara H, Shevach EM: CD4+CD25+ regulatory T cells can mediate suppressor function in the absence of transforming growth factor β1 production and responsiveness. J Exp Med 2002;196:237–246.
11.
Chen W, Jin W, Hardegen N, Lei KJ, Li L, Marinos N, McGrady G, Wahl SM: Conversion of peripheral CD4+CD25-naive T cells to CD4+CD25+ regulatory T cells by TGF-β induction of transcription factor Foxp3. J Exp Med 2003;198:1875–1886.
12.
Marie JC, Letterio JJ, Gavin M, Rudensky AY: TGF-β1 maintains suppressor function and Foxp3 expression in CD4+CD25+ regulatory T cells. J Exp Med 2005;201:1061–1067.
13.
Andersson J, Tran DQ, Pesu M, Davidson TS, Ramsey H, O’Shea JJ, Shevach EM: CD4+ Foxp3+ regulatory T cells confer infectious tolerance in a TGF-β-dependent manner. J Exp Med 2008;205:1975–1981.
14.
DiPaolo RJ, Brinster C, Davidson TS, Andersson J, Glass D, Shevach EM: Autoantigen-specific TGFβ-induced Foxp3+ regulatory T cells prevent autoimmunity by inhibiting dendritic cells from activating autoreactive T cells. J Immunol 2007;179:4685–4693.
15.
Wei HX, Chuang YH, Li B, Wei H, Sun R, Moritoki Y, Gershwin ME, Lian ZX, Tian Z: CD4+ CD25+ Foxp3+ regulatory T cells protect against T cell-mediated fulminant hepatitis in a TGF-β-dependent manner in mice. J Immunol 2008;181:7221–7229.
16.
Derynck R, Zhang YE: Smad-dependent and Smad-independent pathways in TGF-β family signalling. Nature 2003;425:577–584.
17.
Yang X, Letterio JJ, Lechleider RJ, Chen L, Hayman R, Gu H, Roberts AB, Deng C: Targeted disruption of Smad3 results in impaired mucosal immunity and diminished T cell responsiveness to TGF-β. EMBO J 1999;18:1280–1291.
18.
Ashcroft GS, Yang X, Glick AB, Weinstein M, Letterio JL, Mizel DE, Anzano M, Greenwell-Wild T, Wahl SM, Deng C, Roberts AB: Mice lacking Smad3 show accelerated wound healing and an impaired local inflammatory response. Nat Cell Biol 1999;1:260–266.
19.
Datto MB, Frederick JP, Pan L, Borton AJ, Zhuang Y, Wang XF: Targeted disruption of Smad3 reveals an essential role in transforming growth factor β-mediated signal transduction. Mol Cell Biol 1999;19:2495–2504.
20.
Anthoni M, Wang G, Deng C, Wolff HJ, Lauerma AI, Alenius HT: Smad3 signal transducer regulates skin inflammation and specific IgE response in a murine model of atopic dermatitis. J Invest Dermatol 2007;127:1923–1929.
21.
Anthoni M, Fyhrquist-Vanni N, Wolff H, Alenius H, Lauerma A: Transforming growth factor-β/Smad3 signalling regulates inflammatory responses in a murine model of contact hypersensitivity. Br J Dermatol 2008;159:546–554.
22.
Lauerma AI, Fenn B, Maibach HI: Trimellitic anhydride-sensitive mouse as an animal model for contact urticaria. J Appl Toxicol 1997;17:357–360.
23.
Lehto M, Koivuluhta M, Wang G, Amghaiab I, Majuri ML, Savolainen K, Turjanmaa K, Wolff H, Reunala T, Lauerma A, Palosuo T, Alenius H: Epicutaneous natural rubber latex sensitization induces T helper 2-type dermatitis and strong prohevein-specific IgE response. J Invest Dermatol 2003;120:633–640.
24.
Savinko T, Lauerma A, Lehtimaki S, Gombert M, Majuri ML, Fyhrquist-Vanni N, Dieu-Nosjean MC, Kemeny L, Wolff H, Homey B, Alenius H: Topical superantigen exposure induces epidermal accumulation of CD8+ T cells, a mixed Th1/Th2-type dermatitis and vigorous production of IgE antibodies in the murine model of atopic dermatitis. J Immunol 2005;175:8320–8326.
25.
Tsuji RF, Kawikova I, Ramabhadran R, Akahira-Azuma M, Taub D, Hugli TE, Gerard C, Askenase PW: Early local generation of C5a initiates the elicitation of contact sensitivity by leading to early t cell recruitment. J Immunol 2000;165:1588–1598.
26.
Ying S, Robinson DS, Meng Q, Barata LT, McEuen AR, Buckley MG, Walls AF, Askenase PW, Kay AB: C-C chemokines in allergen-induced late-phase cutaneous responses in atopic subjects: Association of eotaxin with early 6-hour eosinophils, and of eotaxin-2 and monocyte chemoattractant protein-4 with the later 24-hour tissue eosinophilia, and relationship to basophils and other C-C chemokines (monocyte chemoattractant protein-3 and RANTES). J Immunol 1999;163:3976–3984.
27.
Appelberg R: Macrophage inflammatory proteins MIP-1 and MIP-2 are involved in T cell-mediated neutrophil recruitment. J Leukoc Biol 1992;52:303–306.
28.
Sallusto F, Baggiolini M: Chemokines and leukocyte traffic. Nat Immunol 2008;9:949–952.
29.
Schaerli P, Ebert L, Willimann K, Blaser A, Roos RS, Loetscher P, Moser B: A skin-selective homing mechanism for human immune surveillance T cells. J Exp Med 2004;199:1265–1275.
30.
Zingoni A, Soto H, Hedrick JA, Stoppacciaro A, Storlazzi CT, Sinigaglia F, D’Ambrosio D, O’Garra A, Robinson D, Rocchi M, Santoni A, Zlotnik A, Napolitano M: The chemokine receptor CCR8 is preferentially expressed in Th2 but not Th1 cells. J Immunol 1998;161:547–551.
31.
Sallusto F, Mackay CR, Lanzavecchia A: The role of chemokine receptors in primary, effector, and memory immune responses. Annu Rev Immunol 2000;18:593–620.
32.
Cattani F, Gallese A, Mosca M, Buanne P, Biordi L, Francavilla S, Coletti G, Pellegrini L, Melillo G, Bertini R: The role of CXCR2 activity in the contact hypersensitivity response in mice. Eur Cytokine Netw 2006;17:42–48.
33.
Traidl C, Merk HF, Cavani A, Hunzelmann N: New insights into the pathomechanisms of contact dermatitis by the use of transgenic mouse models. Skin Pharmacol Appl Skin Physiol 2000;13:300–312.
34.
Harris NL, Watt V, Ronchese F, Le Gros G: Differential T cell function and fate in lymph node and nonlymphoid tissues. J Exp Med 2002;195:317–326.
35.
Dearman RJ, Kimber I: Cytokine fingerprinting and hazard assessment of chemical respiratory allergy. J Appl Toxicol 2001;21:153–163.
36.
Gorelik L, Flavell RA: Immune-mediated eradication of tumors through the blockade of transforming growth factor-β signaling in T cells. Nat Med 2001;7:1118–1122.
37.
Szczepanik M, Bryniarski K, Tutaj M, Ptak M, Skrzeczynska J, Askenase PW, Ptak W: Epicutaneous immunization induces αβ T-cell receptor CD4 CD8 double-positive non-specific suppressor T cells that inhibit contact sensitivity via transforming growth factor-β. Immunology 2005;115:42–54.
38.
Zhao J, Shi W, Wang YL, Chen H, Bringas P, Jr., Datto MB, Frederick JP, Wang XF, Warburton D: Smad3 deficiency attenuates bleomycin-induced pulmonary fibrosis in mice. Am J Physiol Lung Cell Mol Physiol 2002;282:L585–593.
39.
Herzinger T, Kleuser B, Schafer-Korting M, Korting HC: Sphingosine-1-phosphate signaling and the skin. Am J Clin Dermatol 2007;8:329–336.
40.
Gett AV, Sallusto F, Lanzavecchia A, Geginat J: T cell fitness determined by signal strength. Nat Immunol 2003;4:355–360.
41.
Luger TA, Schwarz T, Krutmann J, Kock A, Urbanski A, Kirnbauer R: Cytokines and the skin. Curr Problems Dermatol 1990;19:35–49.
42.
Akiba H, Kehren J, Ducluzeau MT, Krasteva M, Horand F, Kaiserlian D, Kaneko F, Nicolas JF: Skin inflammation during contact hypersensitivity is mediated by early recruitment of CD8+ T cytotoxic 1 cells inducing keratinocyte apoptosis. J Immunol 2002;168:3079–3087.
43.
Dearman RJ, Moussavi A, Kemeny DM, Kimber I: Contribution of CD4+ and CD8+ T lymphocyte subsets to the cytokine secretion patterns induced in mice during sensitization to contact and respiratory chemical allergens. Immunology 1996;89:502–510.
44.
Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL, Murphy KM, Weaver CT: Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 2005;6:1123–1132.
45.
Kaplan G, Luster AD, Hancock G, Cohn ZA: The expression of a γ-interferon-induced protein (IP-10) in delayed immune responses in human skin. J Exp Med 1987;166:1098–1108.
46.
Cavani A, Albanesi C, Traidl C, Sebastiani S, Girolomoni G: Effector and regulatory T cells in allergic contact dermatitis. Trends Immunol 2001;22:118–120.
47.
Albanesi C, Scarponi C, Cavani A, Federici M, Nasorri F, Girolomoni G: Interleukin-17 is produced by both Th1 and Th2 lymphocytes, and modulates interferon-γ- and interleukin-4-induced activation of human keratinocytes. J Invest Dermatol 2000;115:81–87.
48.
Park H, Li Z, Yang XO, Chang SH, Nurieva R, Wang YH, Wang Y, Hood L, Zhu Z, Tian Q, Dong C: A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 2005;6:1133–1141.
49.
Weaver CT, Hatton RD, Mangan PR, Harrington LE: IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu Rev Immunol 2007;25:821–852.
50.
Hue S, Ahern P, Buonocore S, Kullberg MC, Cua DJ, McKenzie BS, Powrie F, Maloy KJ: Interleukin-23 drives innate and T cell-mediated intestinal inflammation. J Exp Med 2006;203:2473–2483.
51.
Albanesi C, Scarponi C, Sebastiani S, Cavani A, Federici M, De Pita O, Puddu P, Girolomoni G: IL-4 enhances keratinocyte expression of CXCR3 agonistic chemokines. J Immunol 2000;165:1395–1402.
52.
Sallusto F, Lanzavecchia A, Mackay CR: Chemokines and chemokine receptors in T-cell priming and Th1/Th2-mediated responses. Immunol Today 1998;19:568–574.
53.
Forster R, Davalos-Misslitz AC, Rot A: CCR7 and its ligands: balancing immunity and tolerance. Nat Rev Immunol 2008;8:362–371.
54.
Seneviratne SL, Black AP, Jones L, di Gleria K, Bailey AS, Ogg GS: Interleukin-4 promotes human CD8 T cell expression of CCR7. Immunology 2007;120:66–72.
55.
Sallusto F, Lenig D, Mackay CR, Lanzavecchia A: Flexible programs of chemokine receptor expression on human polarized T helper 1 and 2 lymphocytes. J Exp Med 1998;187:875–883.
56.
Epperly MW, Franicola D, Zhang X, Nie S, Wang H, Bahnson AB, Shields DS, Goff JP, Shen H, Greenberger JS: Reduced irradiation pulmonary fibrosis and stromal cell migration in Smad3–/– marrow chimeric mice. In Vivo 2006;20:573–582.
57.
Malek D, Gust R, Kleuser B: 17β-Estradiol inhibits transforming-growth-factor-β-induced MCF-7 cell migration by Smad3-repression. Eur J Pharmacol 2006;534:39–47.
58.
Hori S, Nomura T, Sakaguchi S: Control of regulatory T cell development by the transcription factor Foxp3. Science 2003;299:1057–1061.
59.
Fontenot JD, Gavin MA, Rudensky AY: Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 2003;4:330–336.
60.
Kullberg MC, Hay V, Cheever AW, Mamura M, Sher A, Letterio JJ, Shevach EM, Piccirillo CA: TGF-β1 production by CD4+ CD25+ regulatory T cells is not essential for suppression of intestinal inflammation. Eur J Immunol 2005;35:2886–2895.
61.
Shevach EM, Davidson TS, Huter EN, Dipaolo RA, Andersson J: Role of TGF-β in the induction of Foxp3 expression and T regulatory cell function. J Clin Immunol 2008;28:640–646.
62.
Weiss E, Mamelak AJ, La Morgia S, Wang B, Feliciani C, Tulli A, Sauder DN: The role of interleukin 10 in the pathogenesis and potential treatment of skin diseases. J Am Acad Dermatol 2004;50:657–675; quiz 676–678.
63.
Fiorentino DF, Bond MW, Mosmann TR: Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J Exp Med 1989;170:2081–2095.
64.
Hawrylowicz CM: Regulatory T cells and IL-10 in allergic inflammation. J Exp Med 2005;202:1459–1463.
© 2009 S. Karger AG, Basel
2009
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.